Arcus Biosciences Ownership | Who Owns Arcus Biosciences?
Arcus Biosciences Ownership Summary
Arcus Biosciences is owned by 64.99% institutional investors, 6.42% insiders, and 28.59% retail investors. Gilead sciences is the largest institutional shareholder, holding 32.89% of RCUS shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 4.00% of its assets in Arcus Biosciences shares.
RCUS Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Arcus Biosciences | 64.99% | 6.42% | 28.59% |
Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Gilead sciences | 30.06M | 32.89% | $447.61M |
Blackrock | 9.76M | 11.33% | $148.69M |
Blackrock funding, inc. /de | 9.69M | 10.61% | $144.35M |
Vanguard group | 5.39M | 5.90% | $80.25M |
Fmr | 4.05M | 4.43% | $60.34M |
Woodline partners lp | 3.52M | 3.86% | $52.47M |
State street | 2.99M | 3.28% | $44.58M |
Point72 asset management | 2.00M | 2.18% | $29.72M |
Invus financial advisors | 1.61M | 1.87% | $24.55M |
Dimensional fund advisors lp | 1.70M | 1.86% | $25.35M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Gilead sciences | 30.06M | 28.86% | $447.61M |
Invus financial advisors | 1.61M | 27.51% | $24.55M |
Decheng capital | 808.79K | 2.58% | $12.04M |
Parkman healthcare partners | 1.27M | 2.53% | $18.97M |
Boxer capital | 1.60M | 1.28% | $24.40M |
Siren | 1.61M | 1.06% | $24.00M |
Dafna capital management | 254.22K | 0.96% | $3.79M |
Ikarian capital | 378.36K | 0.77% | $5.63M |
Sectoral asset management | 69.55K | 0.69% | $1.04M |
Woodline partners lp | 3.52M | 0.35% | $52.47M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Gilead sciences | 30.06M | 28.86% | 30.06M |
Braidwell lp | 802.10K | 0.35% | 802.10K |
Millennium management | 924.37K | 0.01% | 679.27K |
Bnp paribas asset management | 1.52M | 0.06% | 590.74K |
Adage capital partners gp | 443.00K | 0.01% | 443.00K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Alliancebernstein | 72.51K | 0.00% | -1.23M |
Schonfeld strategic advisors | 135.00K | 0.01% | -538.84K |
Point72 asset management | 2.00M | 0.07% | -440.79K |
Morgan stanley | 445.88K | 0.00% | -429.00K |
Fmr | 4.05M | 0.00% | -415.04K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Gilead sciences | 30.06M | 28.86% | 30.06M | $447.61M |
Braidwell lp | 802.10K | 0.35% | 802.10K | $11.94M |
Adage capital partners gp | 443.00K | 0.01% | 443.00K | $6.60M |
Readystate asset management lp | 351.36K | 0.16% | 351.36K | $5.23M |
Connor, clark & lunn investment management | 64.04K | 0.00% | 64.04K | $953.60K |
Sold Out
Holder | Change |
---|---|
Dinuzzo private wealth | -1.00 |
Farther finance advisors | -1.00 |
Sjs investment consulting | -5.00 |
Jfs wealth advisors | -7.00 |
Massmutual trust co fsb/adv | -7.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | 119 | -37.70% | 59,398,024 | 11.54% | 64 | 1.91% | 52 | -40.91% | 38 | -46.48% |
Sep 30, 2024 | 190 | -4.52% | 53,251,839 | 2.50% | 58 | 1.79% | 89 | -16.82% | 70 | 16.67% |
Jun 30, 2024 | 196 | 8.89% | 51,943,543 | -1.54% | 60 | 1.19% | 106 | 27.71% | 59 | 5.36% |
Mar 31, 2024 | 180 | -8.16% | 52,758,521 | -0.09% | 71 | 1.42% | 83 | -5.68% | 56 | -17.65% |
Dec 31, 2023 | 196 | -1.51% | 52,803,736 | 0.14% | 70 | 1.36% | 88 | 8.64% | 68 | -8.11% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
iShares Core S&P Small-Cap ETF | 4.24M | 4.00% | 2.94K |
Vanguard Total Stock Mkt Idx Inv | 2.15M | 2.04% | 572.20K |
Vanguard US Total Market Shares ETF | 1.62M | 1.53% | - |
Fidelity Select Biotechnology | 1.56M | 1.47% | 170.53K |
iShares Russell 2000 ETF | 1.44M | 1.36% | -12.48K |
SPDR® S&P Biotech ETF | 1.38M | 1.30% | -14.74K |
Vanguard Institutional Extnd Mkt Idx Tr | 1.02M | 0.97% | 209.46K |
Fidelity Select Pharmaceuticals Port | 986.52K | 0.93% | 226.52K |
Fidelity Select Health Care | 949.76K | 0.90% | 249.76K |
CT (Lux) American Smaller Com 9U USD | 906.88K | 0.86% | 55.03K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Feb 27, 2025 | KANEKO YASUNORI | - | Buy | $201.20K |
Feb 27, 2025 | ROSEN TERRY J | Chief Executive Officer | Buy | $201.47K |
Feb 18, 2025 | GILEAD SCIENCES, INC. | - | Buy | $15.00M |
Dec 31, 2024 | Goeltz II Robert C. | Chief Financial Officer | Sell | $53.91K |
Dec 02, 2024 | Azoy Alexander | Chief Accounting Officer | Sell | $3.08K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q1 | 3 | - |
2024 Q4 | - | 2 |
2024 Q3 | - | 1 |
2024 Q2 | - | - |
2024 Q1 | 1 | 9 |
RCUS Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools